{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-099660","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2025-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.775466+00:00","generated_at":"2026-05-17T03:44:00.193089+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mallinckrodt issues 45,564 preferred shares per ordinary share to enable potential Par Health spin-off","bullets":["Issued 45,564 preferred shares for each ordinary share held as of Oct 8, 2025, effective Oct 10, 2025.","Preferred shares have no voting or dividend rights; redeemable at board's discretion for nil consideration.","Transfer restricted: must be in blocks of 45,564 with a stapled ordinary share transfer.","Authorized share capital increased to $3.005B and €25k, creating 3 trillion preferred shares.","Board has not yet authorized the potential spin-off of Par Health; this issuance is preparatory."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-099660","json":"https://secwatch.observer/filing/0001104659-25-099660.json","markdown":"https://secwatch.observer/filing/0001104659-25-099660.md","text":"https://secwatch.observer/filing/0001104659-25-099660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000110465925099660/0001104659-25-099660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000110465925099660/tm2528698d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:44:00.193089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c642a9dfccd6a18ce244e8b6c2cec610caf10ec","claim":"Keenova Therapeutics plc: Issuance of 45,564 preferred shares per outstanding ordinary share was declared on October 10, 2025, with terms including no voting rights, no dividends, optional redemption, limited liquidation preference, and transferability subject to a staple condition (effective 2025-10-10).","evidence_excerpt":"On October 10, 2025, Mallinckrodt plc (the “ Company ”) declared the issuance (the “ Issuance ”) of 45,564 preferred shares, par value US$0.001 per share (each, a “ Preferred Share ”), of the Company for each outstanding ordinary share, par value US$0.01 per share (the “ Ordinary Shares ”), of the Company to shareholders of record as of the close of business on October 8, 2025 (the “ Record Date ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465925099660/0001104659-25-099660-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Effective","value":"2025-10-10"}],"fact_type":"governance_change"},{"claim_id":"b493a07f0d2625f593210468acf9a247d686509b","claim":"Keenova Therapeutics plc: Shareholders approved a subdivision and increase of authorized share capital to US$3,005,000,000 and €25,000, divided into 500,000,000 Ordinary Shares, 3,000,000,000,000 Preferred Shares, and 25,000 Ordinary A Shares, effective October 8, 2025 (effective 2025-10-08).","evidence_excerpt":"On October 8, 2025, the shareholders of the Company, approved an ordinary resolution to subdivide and increase the authorized share capital of the Company to US$3,005,000,000 and €25,000 divided into 500,000,000 Ordinary Shares of US$0.01 each, 3,000,000,000,000 Preferred Shares of US$0.001 each and 25,000 Ordinary A Shares of €1.00 each.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465925099660/0001104659-25-099660-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-10-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}